BBA
LGND icon

Baader Bank Aktiengesellschaft’s Ligand Pharmaceuticals LGND Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,062
Closed -$361K – 543
2025
Q3 		$361K Buy
+2,062
New +$307K 0.02% 373

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Baader Bank Aktiengesellschaft's LGND Position: Q4 2025 in Review

Baader Bank Aktiengesellschaft sold out of Ligand Pharmaceuticals (LGND) in Q4 2025, closing a stake of 2,062 shares — an estimated $361K sold.

Baader Bank Aktiengesellschaft first reported a position in LGND in Q3 2025 and held it in 1 quarter. The position peaked at $361K in Q3 2025. 350 funds tracked by Wall St. Rank hold LGND as of Q4 2025.

  • Baader Bank Aktiengesellschaft reported no remaining Ligand Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Baader Bank Aktiengesellschaft sold 2,062 Ligand Pharmaceuticals shares in Q4 2025, an estimated $361K.
  • Baader Bank Aktiengesellschaft first reported a position in Ligand Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Baader Bank Aktiengesellschaft's Ligand Pharmaceuticals position peaked at $361K in Q3 2025.
  • 350 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2025.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q4 2025, filed 5 Feb 2026.